Novartis AG Company Profile (VTX:NOVN)

About Novartis AG (VTX:NOVN)

Novartis AG logoNovan, Inc., a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris. The company’s product candidates also include SB206, SB208, and SB414, which are targeted toward the treatment of either a specific microorganism or inflammatory components of disease pathology. The company has a license agreement with Sato Pharmaceutical Co., Ltd. Novan, Inc. was founded in 2006 and is headquartered in Morrisville, North Carolina.

Industry, Sector and Symbol: Average Prices:
  • 50 Day Moving Avg: CHF 6.31
  • 200 Day Moving Avg: CHF 6.31
P/E:
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Dividend:
  • Dividend Yield: 1.0%
Profitability:
  • Net Margins: 15.84%
  • Return on Equity: 11.55%
  • Return on Assets: 5.97%
 

Frequently Asked Questions for Novartis AG (VTX:NOVN)

What is Novartis AG's stock symbol?

Novartis AG trades on the VTX under the ticker symbol "NOVN."

Where is Novartis AG's stock going? Where will Novartis AG's stock price be in 2017?

14 equities research analysts have issued 1-year price objectives for Novartis AG's shares. Their forecasts range from CHF 75 to CHF 97. On average, they expect Novartis AG's share price to reach CHF 85.50 in the next year. View Analyst Ratings for Novartis AG.

Who are some of Novartis AG's key competitors?

Who are Novartis AG's key executives?

Novartis AG's management team includes the folowing people:

  • Joseph S. Jimenez, Chief Executive Officer, Member of the Executive Committee
  • Harry Kirsch, Chief Financial Officer, Member of the Executive Committee
  • Michael Ball, Chief Executive Officer of Alcon, Member of the Executive Committee
  • James Bradner M.D., President of the Novartis Institutes for BioMedical Research (NIBR), Member of the Executive Committee
  • Richard D. Francis, Chief Executive Officer of Sandoz Division, Member of the Executive Committee
  • Paul Hudson, Chief Executive Officer of Novartis Pharmaceuticals, Member of the Executive Committee
  • Bruno Strigini, Chief Executive Officer of Novartis Oncology, Member of the Executive Committee
  • Felix R. Ehrat Ph.D., Group General Counsel, Member of the Executive Committee
  • Steven Baert, Head of Human Resources, Member of the Executive Committee
  • Vasant Narasimhan M.D., Global Head of Drug Development and Chief Medical Officer for Novartis, Member of the Executive Committee


MarketBeat Community Rating for Novartis AG (VTX NOVN)
Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  51 (Vote Outperform)
Underperform Votes:  69 (Vote Underperform)
Total Votes:  120
MarketBeat's community ratings are surveys of what our community members think about Novartis AG and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Novartis AG (VTX:NOVN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 6 Hold Ratings, 7 Buy Ratings
Consensus Rating:Hold (Score: 2.43)
Consensus Price Target: CHF 85.50

Analysts' Ratings History for Novartis AG (VTX:NOVN)
Show:
DateFirmActionRatingPrice TargetDetails
9/19/2017HSBC Holdings plcSet Price TargetBuyCHF 90View Rating Details
8/28/2017Kepler Capital MarketsSet Price TargetBuyCHF 87View Rating Details
8/8/2017Goldman Sachs Group IncSet Price TargetNeutralCHF 80View Rating Details
8/4/2017Baader BankSet Price TargetBuyCHF 90View Rating Details
7/26/2017Morgan StanleySet Price TargetBuyCHF 88View Rating Details
7/24/2017Jefferies Group LLCSet Price TargetBuyCHF 97View Rating Details
7/19/2017J P Morgan Chase & CoSet Price TargetNeutralCHF 75View Rating Details
7/19/2017Societe GeneraleSet Price TargetBuyCHF 91View Rating Details
7/19/2017Deutsche Bank AGSet Price TargetNeutralCHF 81View Rating Details
7/18/2017Sanford C. BernsteinSet Price TargetBuyCHF 94View Rating Details
7/18/2017S&P GlobalSet Price TargetNeutralCHF 82View Rating Details
7/14/2017Berenberg BankSet Price TargetNeutralCHF 85View Rating Details
7/5/2017Credit Suisse GroupSet Price TargetSellCHF 77View Rating Details
6/23/2017Barclays PLCSet Price TargetNeutralCHF 80View Rating Details
(Data available from 9/26/2015 forward)

Earnings

Earnings History for Novartis AG (VTX:NOVN)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Novartis AG (VTX:NOVN)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Novartis AG (VTX:NOVN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Novartis AG (VTX:NOVN)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Novartis AG (VTX:NOVN)
Latest Headlines for Novartis AG (VTX:NOVN)
Source:
DateHeadline
americanbankingnews.com logoHSBC Holdings plc Analysts Give Novartis AG (NOVN) a CHF 90 Price Target
www.americanbankingnews.com - September 24 at 2:08 PM
finance.yahoo.com logoNovartis drug Rydapt® (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)
finance.yahoo.com - September 20 at 6:56 AM
reuters.com logoDrug industry on tenterhooks as Maryland price-gouging law nears
www.reuters.com - September 16 at 7:03 AM
finance.yahoo.com logoSandoz proposed biosimilar adalimumab matches reference biologic in terms of efficacy and safety in long-term study
finance.yahoo.com - September 14 at 8:22 AM
barrons.com logoNovartis Deal Could Send Xoma Stock to $19 - Barron's
www.barrons.com - September 8 at 6:25 AM
americanbankingnews.com logoNovartis AG (NOVN) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - September 6 at 2:28 AM
finance.yahoo.com logoNovartis names drugs chief as CEO to deliver return to growth - Yahoo Finance
finance.yahoo.com - September 5 at 5:58 AM
finance.yahoo.com logoEuropean stocks drop after North Korea tests its nuclear arsenal - Yahoo Finance
finance.yahoo.com - September 5 at 5:58 AM
finance.yahoo.com logoNovartis landmark Phase III trial shows fingolimod significantly reduces relapses in children and adolescents with MS
finance.yahoo.com - September 5 at 5:58 AM
finance.yahoo.com logoNovartis gene therapy approval signals new cancer treatment era - Yahoo News
finance.yahoo.com - August 31 at 7:58 AM
finance.yahoo.com logoNovartis receives first ever FDA approval for a CAR-T cell therapy, Kymriah(TM) (CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice
finance.yahoo.com - August 31 at 7:57 AM
americanbankingnews.com logoNovartis AG (NOVN) Given a CHF 87 Price Target at Kepler Capital Markets
www.americanbankingnews.com - August 28 at 12:00 PM
americanbankingnews.com logoUBS AG Analysts Give Novartis AG (NOVN) a CHF 78 Price Target
www.americanbankingnews.com - August 28 at 6:32 AM
finance.yahoo.com logoNovartis Phase III CANTOS study demonstrates that targeting inflammation with ACZ885 reduces cardiovascular risk
finance.yahoo.com - August 27 at 8:04 PM
globenewswire.com logoNovartis appoints Bertrand Bodson as Chief Digital Officer - GlobeNewswire (press release)
globenewswire.com - August 25 at 9:16 AM
finance.yahoo.com logoNovartis Kisqali® (ribociclib) receives EU approval as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor
finance.yahoo.com - August 24 at 10:08 AM
finance.yahoo.com logoNovartis appoints Bertrand Bodson as Chief Digital Officer
finance.yahoo.com - August 24 at 10:08 AM
finance.yahoo.com logoNovartis and Medicines for Malaria Venture launch patient trial in Africa for KAF156, a novel compound against multidrug-resistant malaria
finance.yahoo.com - August 21 at 11:37 PM
finance.yahoo.com logoNovan Appoints Paula Brown Stafford, Chief Development Officer, to Board of Directors
finance.yahoo.com - August 17 at 6:15 AM
americanbankingnews.com logoNovartis AG (VTX:NOVN) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - August 12 at 2:56 AM
americanbankingnews.com logoBaader Bank Reiterates CHF 90 Price Target for Novartis AG (VTX:NOVN)
www.americanbankingnews.com - August 6 at 9:06 PM
nasdaq.com logoEylea helps Regeneron smash profit estimates
www.nasdaq.com - August 4 at 3:26 PM
nasdaq.com logoFDA approves leukemia treatment developed by Celgene, Agios - Nasdaq
www.nasdaq.com - August 3 at 6:20 AM
finance.yahoo.com logoNovan's interim CEO outlines future focus
finance.yahoo.com - August 3 at 6:19 AM
nasdaq.com logoExpress Scripts to cover Mylan's EpiPen, exclude rivals - Nasdaq
www.nasdaq.com - August 1 at 3:48 AM
finance.yahoo.com logoNovan Announces Corporate Update Conference Call and Webcast
finance.yahoo.com - July 26 at 5:15 AM
americanbankingnews.com logoGoldman Sachs Group, Inc. (The) Analysts Give Novartis AG (VTX:NOVN) a CHF 80 Price Target
www.americanbankingnews.com - July 23 at 2:26 PM
americanbankingnews.com logoNovartis AG (VTX:NOVN) PT Set at CHF 81 by Deutsche Bank AG
www.americanbankingnews.com - July 19 at 9:15 AM
americanbankingnews.com logoNovartis AG (NOVN) Given a CHF 91 Price Target at Societe Generale
www.americanbankingnews.com - July 19 at 8:53 AM
americanbankingnews.com logoNovartis AG (VTX:NOVN) Given a CHF 75 Price Target at J P Morgan Chase & Co
www.americanbankingnews.com - July 19 at 8:15 AM
americanbankingnews.com logoNovartis AG (VTX:NOVN) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - July 18 at 2:43 PM
marketwatch.com logoEuropean stocks pulled lower by stronger euro
www.marketwatch.com - July 18 at 6:42 AM
americanbankingnews.com logoBerenberg Bank Reiterates "CHF 85" Price Target for Novartis AG (NOVN)
www.americanbankingnews.com - July 15 at 9:40 PM
americanbankingnews.com logoGoldman Sachs Group, Inc. (The) Analysts Give Novartis AG (NOVN) a CHF 80 Price Target
www.americanbankingnews.com - July 15 at 9:40 PM
finance.yahoo.com logoPioneering cancer gene therapy by Novartis backed by US panel - Yahoo News
finance.yahoo.com - July 14 at 6:55 AM
americanbankingnews.com logoCredit Suisse Group Analysts Give Novartis AG (NOVN) a CHF 77 Price Target
www.americanbankingnews.com - July 9 at 11:32 PM
finance.yahoo.com logoNovan to Present Safety and Efficacy Data for SB204 Program in Adolescents at 13th World Congress of Pediatric Dermatology
finance.yahoo.com - July 8 at 1:02 PM
finance.yahoo.com logoAs it pushes forward with its acne drug, Novan's cash dwindles to $30 million
finance.yahoo.com - July 8 at 1:02 PM
americanbankingnews.com logoNovartis AG (VTX:NOVN) PT Set at CHF 80 by Deutsche Bank AG
www.americanbankingnews.com - July 7 at 7:36 AM
americanbankingnews.com logoNovartis AG (VTX:NOVN) Given a CHF 88 Price Target at Kepler Capital Markets
www.americanbankingnews.com - July 4 at 10:30 AM
nasdaq.com logoVectura signs deal with Novartis for generic US lung therapy - Nasdaq
www.nasdaq.com - June 28 at 11:02 PM
nasdaq.com logoAlder's shares tumble as migraine drug data disappoints
www.nasdaq.com - June 27 at 6:58 PM
americanbankingnews.com logoNovartis AG (NOVN) PT Set at CHF 78 by Deutsche Bank AG
www.americanbankingnews.com - June 25 at 6:44 PM
americanbankingnews.com logoJefferies Group LLC Analysts Give Novartis AG (NOVN) a CHF 103 Price Target
www.americanbankingnews.com - June 24 at 8:58 AM
reuters.com logoExclusive: Uruguayan drugmaker taps Jefferies for bond, stock debut, sources say
www.reuters.com - June 24 at 12:26 AM
americanbankingnews.com logoNovartis AG (NOVN) Given a CHF 80 Price Target by Barclays PLC Analysts
www.americanbankingnews.com - June 23 at 7:44 AM
americanbankingnews.com logoNovartis AG (NOVN) Given a CHF 80 Price Target at Goldman Sachs Group Inc
www.americanbankingnews.com - June 21 at 10:44 AM
americanbankingnews.com logoNovartis AG (NOVN) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - June 21 at 7:35 AM
nasdaq.com logoNovartis eye drug works at less frequent dosing than rival's
www.nasdaq.com - June 20 at 7:57 PM
reuters.com logoSupreme Court speeds copycat biologic drugs to market
www.reuters.com - June 13 at 8:57 AM

Social

Social activity is not available for this stock.
This page was last updated on 9/26/2017 by MarketBeat.com Staff